Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
Status:
Completed
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in
subjects with impaired liver function in comparison with healthy subjects